P-22 Role of timing to laparoscopic or robotic surgery after neoadjuvant chemoradiotherapy for rectal cancer: The TiMiSNAR trial

Abstract

Chemoradiotherapy (CRT) is a well-known, risk-reducing treatment of local recurrence in the treatment of rectal cancer, followed by total mesorectal excision (TME). In low rectal tumors, surgery alone has the 30% overall survival and a local recurrence rate of about 55-65%, with a disease-free survival of 30%-35%. Preoperative administration of fluorouracil-based chemotherapy improves local recurrence rates by 7%. The optimal timing of surgery in relation to chemoradiation is still controversial and it is the target of numerous studies, either retrospective or randomized controlled trials.